NOVOTHIRTEEN

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Italy, Japan, Lithuania, Poland, Spain.

Active ingredients

The drug NOVOTHIRTEEN contains one active pharmaceutical ingredient (API):

1	Coagulation factor VIII UNII NU23Q531G1 - CATRIDECACOG
	Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
	Read more about Coagulation factor VIII

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BD11	Catridecacog	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1593424
ES	Centro de información online de medicamentos de la AEMPS	12775001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	169925
IT	Agenzia del Farmaco	043034014
JP	医薬品医療機器総合機構	6343443D1027
LT	Valstybinė vaistų kontrolės tarnyba	1067710
PL	Rejestru Produktów Leczniczych	100288050